Erasca Q2 Net Loss $44.1M; Upsized Offering $632.5M; Clinical Updates
Erasca, Inc. reported a net loss of $44.1 million, or $(0.14) per share, for the second quarter ended June 30, 2026, compared to a net loss of $33.9 million, or $(0.12) per share, for the same period in 2025. The company's cash, cash equivalents, and marketable securities stood at $384.3 million as of June 30, 2026. Erasca also announced the completion of an upsized public offering in July 2026, which raised approximately $632.5 million in gross proceeds, significantly strengthening its balance sheet. Additionally, updated clinical data for ERAS-0015 highlighted compelling monotherapy efficacy in pancreatic cancer and favorable tolerability, with the program advancing toward three potentially registration-enabling trials. Preliminary Phase 1 monotherapy data for ERAS-4001 is anticipated in the second half of 2026.
Key Highlights
- Net loss for Q2 2026 was $44.1 million, compared to $33.9 million in Q2 2025.
- Net loss per share for Q2 2026 was $(0.14), compared to $(0.12) in Q2 2025.
- Cash, cash equivalents, and marketable securities totaled $384.3 million as of June 30, 2026.
- Completed an upsized public offering in July 2026, raising $632.5 million in gross proceeds.
- Research and Development (R&D) expenses increased to $35.9 million in Q2 2026 from $21.2 million in Q2 2025.
- ERAS-0015 showed 57% uORR8wk in 2L+ KRAS G12X PDAC with favorable tolerability.
- ERAS-0015 program is advancing toward three potentially registration-enabling trials in pancreatic and lung cancers.
- Preliminary Phase 1 monotherapy data for ERAS-4001 is expected in H2 2026.
Price Impact
More from ERAS